How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non- 18F-FDG PET radiopharmaceuticals

Nuclear Medicine Communications

Volumn 33, Issue 7, 2012, Pages 679-688

  Wong, Ka Kit ^a,b   Laird, Amanda M ^a,b   Moubayed, Amir ^a   Chondrogiannis, Sotirios ^c   Marzola, Maria Cristina ^a   Evangelista, Laura ^d   Gross, Milton D ^a,b   Rubello, Domenico ^c  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c Santa Maria della Misericordia Hospital   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

18F fluorodeoxyglucose; 18F fluorodihydroxyphenylalanine; conventional imaging; medullary thyroid cancer; PET; restaging; staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LEVODOPA; SOMATOSTATIN;

CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; GENETIC SCREENING; HUMAN; LYMPH NODE METASTASIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84862238171     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283529bf7     Document Type: Review

References (79)

1. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010; 22:475-485.
2. Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: Early detection and novel treatments. Curr Opin Oncol 2009; 21:5-10.
3. Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: An update of new guidelines and recent developments. Curr Opin Oncol 2011; 23:22-27.
4. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107:2134-2142.
5. Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: Diagnostic strategies and treatment. J Clin Endocrinol Metab 2011; 96:1237-1245.
6. Dackiw AP. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am 2010; 43:365-374, ix.
7. Moley JF. Medullary thyroid carcinoma: Management of lymph node metastases. J Natl Compr Canc Netw 2010; 8:549-556.
8. Noullet S, Tresallet C, Godiris-Petit G, Hoang C, Leenhardt L, Menegaux F. Surgical management of sporadic medullary thyroid cancer. J Visc Surg 2011; 148:e244-e249.
9. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775-783.
10. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009; 19:565-612.
11. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, et al. Medullary carcinoma. J Natl Compr Canc Netw 2010; 8:512-530.
12. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 2005; 200:890-896.
13. Witt RL. What is the treatment of the lateral neck in clinically localized sporadic medullary thyroid cancer? Laryngoscope 2010; 120:1286-1287.
14. Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008; 62:139-146.
15. Wong KK, Arabi M, Zerizer I, Al-Nahhas A, Rubello D, Gross MD. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: Fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl Med Commun 2011; 32:764-781.
16. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501-507.
17. Szakall S Jr., Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43:66-71.
18. Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun 2010; 31:567-575.
19. Vezzosi D, Bennet A, Caron P. Recent advances in treatment of medullary thyroid carcinoma. Ann Endocrinol (Paris) 2007; 68 (2-3):147-153.
20. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658-5671.
21. Wohllk N, Schweizer H, Erlic Z, Schmid KW,Walz MK, Raue F, et al. Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 2010; 24:371-387.
22. Grubbs EG, Waguespack SG, Rich TA, Xing Y, Ying AK, Evans DB, et al. Do the recent American Thyroid Association (ATA) guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A? Surgery 2010; 148:1302-1309, discussion 9-10.
23. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 2001; 28:1671-1676.
24. Beheshti M, Pocher S, Vali R,Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: Comparison with 18F-FDG PET-CT. Eur Radiol 2009; 19:1425-1434.
25. Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008; 207:259-264.
26. Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: Prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009; 30:742-748.
27. Ito Y, Miyauchi A, Yabuta T, Fukushima M, Inoue H, Tomoda C, et al. Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: Experience of a single institution. World J Surg 2009; 33:58-66.
28. Sipos JA. Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid 2009; 19:1363-1372.
29. Adams S, Acker P, Lorenz M, Staib-Sebler E, Hor G. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma: A comparison of preoperative and intraoperative tumor localization with histopathologic findings. Cancer 2001; 92: 263-270.
30. Shimotake T, Tsuda T, Aoi S, Fumino S, Iwai N. Iodine-123 metaiodobenzylguanidine radio-guided navigation surgery for recurrent medullary thyroid carcinoma in a girl with multiple endocrine neoplasia type 2B. J Pediatr Surg 2005; 40:1643-1646.
31. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1994; 21: 363-364.
32. Curtet C, Carlier T, Mirallie E, Bodet-Milin C, Rousseau C, Barbet J, et al. Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: In vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. Eur J Nucl Med Mol Imaging 2007; 34:1556-1562.
33. Kraeber-Bodere F, Cariou B, Curtet C, Bridji B, Rousseau C, Dravet F, et al. Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. Surgery 2005; 138:1176-1182, discussion 82.
34. Esik O, Szavcsur P, Szakall S Jr., Bajzik G, Repa I, Dabasi G, et al. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma. Cancer 2001; 91:2084-2095.
35. Tai D, Poon D. Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. J Oncol 2010; 2010: Article ID 398564. [Accessed 13 March 2012].
36. Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 2010; 102:175-178.
37. Biermann K, Biersack HJ, Sabet A, Janzen V. Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nucl Med 2011; 41:139-148.
38. Divgi C. Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 2011; 41:369-373.
39. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: A new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011; 7:617-624.
40. Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol 2011; 9:391-394.
41. Prazeres H, Torres J, Rodrigues F, Couto JP, Vinagre J, Sobrinho-Simoes M, et al. How to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer. J Thyroid Res 2011; published online 23 June 2011, doi: 10.4061/2011/678357.
42. Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 2010; 31:578-599.
43. Deshpande H, Roman S, Thumar J, Sosa JA. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clin Med Insights Oncol 2011; 5:213-221.
44. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hor G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998; 25:1277-1283.
45. Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 2003; 30:22-25.
46. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27:490-496.
47. De Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11:786-794.
48. Gasparoni P, Rubello D, Ferlin G. Potential role of fluorine-18- deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997; 20: 527-530.
49. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185-4190.
50. Gotthardt M, Battmann A, Hoffken H, Schurrat T, Pollum H, Beuter D, et al. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: A clinical study and an analysis of the literature. Nucl Med Commun 2004; 25:439-443.
51. Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol 2007; 9:72-77.
52. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007; 92: 4590-4597.
53. Bozkurt MF, Ugur O, Banti E, Grassetto G, Rubello D. Functional nuclear medicine imaging of medullary thyroid cancer. Nucl Med Commun 2008; 29:934-942.
54. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79-83.
55. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-Dglucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol 2010; 12: 547-553.
56. Czepczynski R, Parisella MG, Kosowicz J, Mikolajczak R, Ziemnicka K, Gryczynska M, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007; 34:1635-1645.
57. Parisella M, D'Alessandria C, van de Bossche B, Chianelli M, Ronga G, Papini E, et al. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm 2004; 19:211-217.
58. Iagaru A, Masamed R, Singer PA, Conti PS. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol 2006; 8:309-314.
59. Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective study. Eur J Surg Oncol 2008; 34: 581-586.
60. Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:46-48.
61. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: Current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008; 52:419-429.
62. Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol 2008; 35 (Suppl 1):S27-S34.
63. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med 2008; 49:573-586.
64. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, et al. Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 2009; 71:199-213.
65. Minn H, Kauhanen S, Seppanen M, Nuutila P. 18F-DOPA: A multiple-target molecule. J Nucl Med 2009; 50:1915-1918.
66. Mottaghy FM, Reske SN. Functional imaging of neuroendocrine tumours with PET. Pituitary 2006; 9:237-242.
67. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007; 48:1599-1606.
68. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18FDOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28:64-71.
69. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-Dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Relation to tumor differentiation. J Nucl Med 2008; 49:524-531.
70. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol 2010; 36:414-421.
71. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro- DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007; 34:1604-1609.
72. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20:527-533.
73. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: A new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009; 30:281-286.
74. Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003; 88:637-641.
75. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: Role of positron emission tomography. Endocr Rev 2004; 25: 568-580.
76. Al-Nahhas A,Win Z, Szyszko T, Singh A, Nanni C, Fanti S, et al. Gallium-68 PET: A new frontier in receptor cancer imaging. Anticancer Res 2007; 27 (6B):4087-4094.
77. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:49-57.
78. Turker O, Dogan I. The clinical role of molecular imaging: Positron emission tomography/computed tomography and (90)yttrium-DOTATOC in the management of medullary thyroid cancer. Thyroid 2010; 20:233-234.
79. Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, et al. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: Comparison with (18)F-FDG PET/CT. Endocr J 2010; 57:1045-1054.